ENTITY

VolitionRX (VNRX US)

16
Analysis
Health CareUnited States
VolitionRx Limited operates as an epigenetics company. The Company offers a platform to develop and market blood tests designed to diagnose and monitor a range of life-altering diseases, including certain cancers and diseases associated with NETosis such as sepsis and COVID-19. VolitionRx offers its services in the United Kingdom, United States, Singapore, and Belgium.
more
bullishVolitionRX
13 Mar 2018 23:30Issuer-paid

VolitionRx - Results from asymptomatic CRC trial reported

VolitionRx recently announced the initial results from a 680-sample study taken from asymptomatic colorectal cancer (CRC) patients. The study...

Share
bullishVolitionRX
28 Nov 2017 21:28Issuer-paid

VolitionRx - Big EU trials on deck

In September 2017, VolitionRx announced its European development plan for the Nu.Q™ colorectal cancer (CRC) frontline screening test. It will run...

Share
bullishVolitionRX
21 Aug 2017 18:45Issuer-paid

13,500-person prospective US trial on deck

VolitionRx will be participating in a 13,500-patient prospective trial investigating its colorectal Nu.Q™ test (and other biomarkers) in the US....

Share
bullishVolitionRX
16 May 2017 18:00Issuer-paid

Gaining more evidence

In May 2017, VolitionRx presented the final data from its 8,000-person clinical validation study of the Nu.Q™ Colorectal Cancer Screening Triage...

Share
bullishVolitionRX
20 Mar 2017 21:07Issuer-paid

Something innovative in the state of Denmark

VolitionRx recently announced the initiation of a two-phase logistical study for its Nu.Q™ Triage test for colorectal cancer (CRC) in Denmark,...

Share
x